Screener
Kiniksa Pharmaceuticals International, plc KNSA Cash & Equivalents
Cash & Equivalents at other companies
Other financials
Where this comes from
Reported directly by Kiniksa Pharmaceuticals International, plc in its filing.
Tagged under the XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue.
The source filing: Kiniksa Pharmaceuticals International, plc’s 10-Q, filed July 28, 2026.
- Filed
- Jul 28, 2026, 4:17 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001104659-26-087545
| Line item | June 30, 2026 | December 31, 2025 |
|---|---|---|
| Assets | ||
| Current assets: | ||
| Cash and cash equivalents | $175,677 | $165,596 |
| Short-term investments | 350,251 | 248,478 |
| Accounts receivable, net | 23,490 | 15,594 |
| Inventory | 70,930 | 54,895 |
| Prepaid expenses and other current assets | 48,285 | 42,614 |
| Total current assets | 668,633 | 527,177 |
Item 1. Financial Statements (unaudited)
FAQ
- What is Kiniksa Pharmaceuticals International, plc's cash & equivalents?
- Kiniksa Pharmaceuticals International, plc (KNSA) reported cash & equivalents of $175.68M in Q2 2026.
- How has Kiniksa Pharmaceuticals International, plc's cash & equivalents changed year-over-year?
- Kiniksa Pharmaceuticals International, plc's cash & equivalents decreased by 8.5% year-over-year, from $192.04M to $175.68M.
- What is the long-term trend for Kiniksa Pharmaceuticals International, plc's cash & equivalents?
- Over 5 years (2020 to 2025), Kiniksa Pharmaceuticals International, plc's cash & equivalents has grown at a 7.7% compound annual growth rate (CAGR), from $114.04M to $165.6M.
- What does cash & equivalents mean?
- Cash on hand plus highly liquid investments with maturities of three months or less at purchase — treasury bills, money market funds, and commercial paper.
Ask your AI about Kiniksa Pharmaceuticals International, plc's cash & equivalents.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude